CN Patent

CN103509017A — 作为TRK激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物

Assigned to Array Biopharma Inc · Expires 2014-01-15 · 12y expired

What this patent protects

式I的化合物，其中R 1 、R 2 、R 3 、R 4 、X、Y和n具有说明书中所提供的含义，该化合物是Trk激酶的抑制剂且可用于治疗可用Trk激酶抑制剂治疗的疾病。

USPTO Abstract

式I的化合物，其中R 1 、R 2 、R 3 、R 4 、X、Y和n具有说明书中所提供的含义，该化合物是Trk激酶的抑制剂且可用于治疗可用Trk激酶抑制剂治疗的疾病。

Drugs covered by this patent

larotrectinib-sulfate (LAROTRECTINIB SULFATE)

Patent Metadata

Patent number: CN103509017A
Jurisdiction: CN
Classification: —
Expires: 2014-01-15
Drug substance claim: No
Drug product claim: No
Assignee: Array Biopharma Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.